<DOC>
	<DOCNO>NCT00038220</DOCNO>
	<brief_summary>The purpose study see novel 4-drug anti-HIV combination suppress growth HIV patient infect virus .</brief_summary>
	<brief_title>Effectiveness ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Have HIV Infection . Age 18 65 year old . Show sign recent illness HIV infection . Agree use barrier method birth control study 30 day study . Are unable follow study requirement ( opinion investigator ) . Are pregnant breastfeeding . Are unable take medication mouth . Have chronic nausea vomit . Have cancer Kaposi 's sarcoma basal cell carcinoma . Have active , serious infection ( HIV ) require antibiotic injection within 15 day prior screen . Are take medication allow ABT378/r efavirenz . Are take take experimental drug , antiretroviral drug , drug affect immune system within 30 day start study without consent medical monitor . Are receive receive radiation therapy within 30 day start study without consent medical monitor . Have history drug abuse mental illness would prevent patient follow protocol requirement . Have history kidney bone disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>HIV</keyword>
</DOC>